Showing 13 to 24 of 70 results
Limited Uptake of Anti-Obesity Drugs in France Fuels Unregulated Online Market
In France, despite expanded access to anti-obesity drugs Wegovy and Mounjaro since June 23rd, 2025, fewer than 40,000 patients were using them by late June, leading to a burgeoning but unregulated online market with varying prices (€120–€468 monthly) and safety concerns.
Limited Uptake of Anti-Obesity Drugs in France Fuels Unregulated Online Market
In France, despite expanded access to anti-obesity drugs Wegovy and Mounjaro since June 23rd, 2025, fewer than 40,000 patients were using them by late June, leading to a burgeoning but unregulated online market with varying prices (€120–€468 monthly) and safety concerns.
Progress
40% Bias Score
IRA's Impact: Lower Drug Costs for Medicare Cancer Patients
The Inflation Reduction Act capped annual out-of-pocket costs for Medicare Part D prescription drugs at $3,300 in 2024 and $2,000 in 2025, resulting in a 50% year-over-year increase in oncology prescription volumes between 2023 and 2024, significantly benefiting cancer patients.
IRA's Impact: Lower Drug Costs for Medicare Cancer Patients
The Inflation Reduction Act capped annual out-of-pocket costs for Medicare Part D prescription drugs at $3,300 in 2024 and $2,000 in 2025, resulting in a 50% year-over-year increase in oncology prescription volumes between 2023 and 2024, significantly benefiting cancer patients.
Progress
40% Bias Score
Pharma Companies Pledge Billions in US Manufacturing Amid Tariff Threats
Faced with potential tariffs, major US pharmaceutical companies announced over \$250 billion in domestic manufacturing expansions; however, experts doubt this will significantly reduce US reliance on foreign drug sources or lower consumer costs.
Pharma Companies Pledge Billions in US Manufacturing Amid Tariff Threats
Faced with potential tariffs, major US pharmaceutical companies announced over \$250 billion in domestic manufacturing expansions; however, experts doubt this will significantly reduce US reliance on foreign drug sources or lower consumer costs.
Progress
44% Bias Score
High Costs, Inconsistent Coverage Limit Access to Popular Obesity Drugs
High prices and inconsistent insurance coverage limit access to the popular obesity medications Wegovy and Ozempic, despite falling costs and some employer-sponsored plans expanding coverage; the medications cost around $500 per month without insurance, forcing doctors to find creative solutions and...
High Costs, Inconsistent Coverage Limit Access to Popular Obesity Drugs
High prices and inconsistent insurance coverage limit access to the popular obesity medications Wegovy and Ozempic, despite falling costs and some employer-sponsored plans expanding coverage; the medications cost around $500 per month without insurance, forcing doctors to find creative solutions and...
Progress
40% Bias Score
EU Pharma Industry Opposes Retaliatory Tariffs Amid US Drug Import Levy Threat
The European pharmaceutical industry urges the EU against retaliatory tariffs on US drugs, fearing negative consequences for both sides and higher patient costs; the EU faces a July 9th deadline for trade deals with the US, and non-tariff barriers also hamper European competitiveness.
EU Pharma Industry Opposes Retaliatory Tariffs Amid US Drug Import Levy Threat
The European pharmaceutical industry urges the EU against retaliatory tariffs on US drugs, fearing negative consequences for both sides and higher patient costs; the EU faces a July 9th deadline for trade deals with the US, and non-tariff barriers also hamper European competitiveness.
Progress
48% Bias Score
Medicare Drug Price Negotiations Continue Under Trump Administration
The Trump administration is continuing Medicare's drug price negotiations begun under Biden, with initial offers sent to Novo Nordisk and Amgen for 15 drugs; lower prices are expected to start in January 2027.
Medicare Drug Price Negotiations Continue Under Trump Administration
The Trump administration is continuing Medicare's drug price negotiations begun under Biden, with initial offers sent to Novo Nordisk and Amgen for 15 drugs; lower prices are expected to start in January 2027.
Progress
36% Bias Score
Trump Urges Drug Price Cuts, Faces Limited Authority
President Trump sent letters to 17 major pharmaceutical companies on Thursday, urging them to lower drug prices according to his May executive order; however, experts say this amounts to price controls and may prove ineffective without congressional action.
Trump Urges Drug Price Cuts, Faces Limited Authority
President Trump sent letters to 17 major pharmaceutical companies on Thursday, urging them to lower drug prices according to his May executive order; however, experts say this amounts to price controls and may prove ineffective without congressional action.
Progress
40% Bias Score
Trump Administration to Invest $200 Billion in Medicaid
The Trump administration will invest over $200 billion in Medicaid under the "One Big Beautiful Bill," aiming to improve care for vulnerable populations, while also launching a health data-sharing program to improve access to records.
Trump Administration to Invest $200 Billion in Medicaid
The Trump administration will invest over $200 billion in Medicaid under the "One Big Beautiful Bill," aiming to improve care for vulnerable populations, while also launching a health data-sharing program to improve access to records.
Progress
40% Bias Score
CVS Caremark's Weight-Loss Drug Switch Stirs Patient Outrage
CVS Caremark dropped Zepbound (tirzepatide) from its preferred drug list on July 1, 2025, replacing it with Wegovy (semaglutide) due to high costs, prompting negative patient reactions and concerns about treatment disruptions. A study showed Zepbound resulted in greater weight loss than Wegovy.
CVS Caremark's Weight-Loss Drug Switch Stirs Patient Outrage
CVS Caremark dropped Zepbound (tirzepatide) from its preferred drug list on July 1, 2025, replacing it with Wegovy (semaglutide) due to high costs, prompting negative patient reactions and concerns about treatment disruptions. A study showed Zepbound resulted in greater weight loss than Wegovy.
Progress
52% Bias Score
Sanofi's \$150 Million AI Hub in Barcelona: Boosting Innovation, but Slow Approvals Remain a Hurdle
Sanofi is investing \$150 million in a new Barcelona AI and digital hub by 2030, highlighting Spain's role in pharmaceutical research but criticizing slow drug pricing and reimbursement processes impacting patient access and future investment.
Sanofi's \$150 Million AI Hub in Barcelona: Boosting Innovation, but Slow Approvals Remain a Hurdle
Sanofi is investing \$150 million in a new Barcelona AI and digital hub by 2030, highlighting Spain's role in pharmaceutical research but criticizing slow drug pricing and reimbursement processes impacting patient access and future investment.
Progress
44% Bias Score
US GLP-1 Drug Affordability Crisis
High costs and limited insurance coverage of GLP-1 weight-loss drugs like Ozempic and Wegovy are creating an affordability crisis in the US, with millions losing coverage in 2025; potential solutions include allowing compounding pharmacies to produce personalized prescriptions and revoking patent ex...
US GLP-1 Drug Affordability Crisis
High costs and limited insurance coverage of GLP-1 weight-loss drugs like Ozempic and Wegovy are creating an affordability crisis in the US, with millions losing coverage in 2025; potential solutions include allowing compounding pharmacies to produce personalized prescriptions and revoking patent ex...
Progress
52% Bias Score
MSF's Secret Drug Deals Undermine Transparency Campaign
Doctors Without Borders (MSF) signed non-disclosure agreements (NDAs) with pharmaceutical companies, including Bayer, to obtain medicines for low-income countries, contradicting their public advocacy for drug price transparency, due to the power imbalance in supply negotiations.
MSF's Secret Drug Deals Undermine Transparency Campaign
Doctors Without Borders (MSF) signed non-disclosure agreements (NDAs) with pharmaceutical companies, including Bayer, to obtain medicines for low-income countries, contradicting their public advocacy for drug price transparency, due to the power imbalance in supply negotiations.
Progress
44% Bias Score
Showing 13 to 24 of 70 results